INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE)
Paris Cedex 13, FR
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE) Patent applications | ||
Patent application number | Title | Published |
---|---|---|
20110257140 | Biomarkers of Mineralocorticoid Receptor Activation - The present invention relates to the use of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and/or SERPINA3 as biomarkers of the Mineralocorticoid Receptor (MR) activation in a patient. More particularly, the present invention relates to a method for predicting the responsiveness of a patient to a treatment with a MR antagonist or an aldosterone synthase inhibitor, said method comprising determining in a biological sample obtained from said patient the expression level of the NGAL gene and/or of the SERPINA3 gene. | 10-20-2011 |
20100209426 | INHIBITORS OF PROGASTRIN-INDUCED REPRESSION OF ICAT FOR TREATING AND/OR PREVENTING COLORECTAL CANCER, ADENOMATOUS POLYPOSIS OR METASTASIS DISPLAYING PROGASTRIN-SECRETING CELLS AND CELLS IN WHICH THE BETA-CATENIN/TCF-MEDIATED TRANSCRIPTIONAL PATHWAY IS CONSTITUTIVELY ACTIVE - The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active. | 08-19-2010 |